Other languages Wave Life Sciences Ltd.

Equities

WVE

SG9999014716

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
6.18 ^USD	+0.16%		-0.64%	+22.38%

May. 15	Wells Fargo Starts WAVE Life Sciences With Overweight Rating, $11 Price Target	MT
May. 09	Transcript : Wave Life Sciences Ltd., Q1 2024 Earnings Call, May 09, 2024

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference	May. 30
Wave Life Sciences : Improving the Potency and Sequence Versatility of RNA Editing Through Oligonucleotide Chemical Modifications	May. 24
Wave Life Sciences : Impact of Phosphoryl Guanidine (PN) Variants on siRNA Potency and Durability in Hepatic and Extrahepatic Tissues	May. 24
First clinical evidence for myocyte stem (satellite) cell targeting in DMD: Results from Part A of a Phase 1b/2 study of WVE-N531	May. 24
A Phase 1b/2 Open label Study of WVE N531 in Patients with Duchenne Muscular Dystrophy: Part B (FORWARD 53) Study Design and Rationale	May. 24
Wells Fargo Starts WAVE Life Sciences With Overweight Rating, $11 Price Target	May. 15
Wave Life Sciences : Potent, Durable mRNA Knockdown in Extrahepatic Tissues Using siRNAs With Novel Phosphoryl Guanidine Backbone Variants	May. 10
Wave Life Sciences : Chemical Design of Oligonucleotides That Support Targeted RNA Editing in the CNS of Non-Human Primates	May. 09
Transcript : Wave Life Sciences Ltd., Q1 2024 Earnings Call, May 09, 2024	May. 09
Earnings Flash (WVE) WAVE LIFE SCIENCES USA Posts Q1 Revenue $12.5M, vs. Street Est of $23M	May. 09
Wave Life Sciences: Q1 Earnings Snapshot	May. 09
Wave Life Sciences Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update	May. 09
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer	May. 09
Wave Life Sciences Announces Appointment of Erik Ingelsson as Chief Scientific Officer	May. 09
Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference	May. 07
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024	May. 02
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)	Apr. 30
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency	Apr. 30
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing	Apr. 23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Wave Life Sciences Ltd.

Equities

WVE

SG9999014716

Other languages

Filters